Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Lorefice

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Multiple Sclerosis and Related Disorders|July 16, 2023
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered surveyManuela Altieri, Rocco Capuano, Alvino Bisecco, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, et al.
Frontiers in Immunology|September 5, 2022
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up studyMaria Laura Idda, Maristella Pitzalis, Valeria Lodde, et al.
Journal of the Neurological Sciences|March 26, 2021
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian studyStefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
The Journal of Headache and Pain|July 3, 2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosisViviana Nociti, Simone Cesarano, Marina Romozzi, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 8, 2024
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosisMaria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Multiple Sclerosis and Related Disorders|July 16, 2023
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered surveyManuela Altieri, Rocco Capuano, Alvino Bisecco, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, et al.
Frontiers in Immunology|September 5, 2022
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up studyMaria Laura Idda, Maristella Pitzalis, Valeria Lodde, et al.
Journal of the Neurological Sciences|March 26, 2021
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian studyStefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
The Journal of Headache and Pain|July 3, 2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosisViviana Nociti, Simone Cesarano, Marina Romozzi, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 8, 2024
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosisMaria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Pageof 10